Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kamada Ltd. KMDA
$4.89
-$0.06 (-1.21%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
219680720.00000000
-
week52high
5.43
-
week52low
3.72
-
Revenue
129339000
-
P/E TTM
-90
-
Beta
0.24136700
-
EPS
-0.05000000
-
Last Dividend
0.00600000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 02 февр 2018 г. | |
| Jefferies | Buy | Buy | 13 ноя 2015 г. |
| Oppenheimer | Outperform | 25 июн 2013 г. | |
| Morgan Stanley | Equal-Weight | 25 июн 2013 г. | |
| Jefferies | Buy | 25 июн 2013 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Kamada Ltd. (KMDA) Q4 2022 Earnings Call Transcript
Seeking Alpha
15 мар 2023 г. в 16:07
Kamada Ltd. (NASDAQ:KMDA ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Troy Williams - LifeSci Advisors Amir London - CEO Chaime Orlev - CFO Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings.
New Strong Buy Stocks for November 28th
Zacks Investment Research
28 ноя 2022 г. в 09:02
KMDA, SLCA and FTNT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2022.
Kamada Ltd. (KMDA) Q3 2022 Earnings Call Transcript
Seeking Alpha
22 ноя 2022 г. в 10:35
Kamada Ltd. (NASDAQ:KMDA ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Operator Greetings.
Kamada (KMDA) Q3 Earnings and Revenues Top Estimates
Zacks Investment Research
22 ноя 2022 г. в 09:47
Kamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Kamada Ltd. (KMDA) CEO Amir London on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
17 авг 2022 г. в 13:58
Kamada Ltd. (NASDAQ:KMDA ) Q2 2022 Earnings Conference Call August 17, 2022 8:30 AM ET Company Representatives Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Bob Yedid - LifeSci Advisors Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Kamada Ltd.